NCT07231458: A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

Sponsor: Abalos Therapeutics GmbH. Phase: PHASE1. Conditions: Advanced Solid Tumors